Market closed
Crinetics Pharmaceuticals/$CRNX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Ticker
$CRNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
290
Website
CRNX Metrics
BasicAdvanced
$4.9B
Market cap
-
P/E ratio
-$3.72
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$4.9B
Beta
0.57
52-week high
$59.95
52-week low
$33.67
Average daily volume
716K
Financial strength
Current ratio
16.385
Quick ratio
16.235
Long term debt to equity
5.417
Total debt to equity
6.307
Management effectiveness
Return on assets (TTM)
-24.29%
Return on equity (TTM)
-40.26%
Valuation
Price to revenue (TTM)
3,791.789
Price to book
5.12
Price to tangible book (TTM)
5.12
Price to free cash flow (TTM)
-19.353
Growth
Revenue change (TTM)
-78.00%
Earnings per share change (TTM)
2.08%
3-year earnings per share growth (CAGR)
10.12%
What the Analysts think about CRNX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRNX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRNX News
AllArticlesVideos
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
GlobeNewsWire·2 weeks ago
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $4.9B as of December 21, 2024.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of December 21, 2024.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.